Conduit Pharmaceuticals Advances Drug Development with AI Integration Through Sarborg Collaboration

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today is pleased to announce the completion of the first phase of its strategic collaboration with Sarborg Limited. This partnership was initiated in December 2024 to integrate an advanced artificial intelligence and cybernetics technology ("AI") into the Company's operations, marking a transformative step in how Conduit would develop and deliver drug development. By leveraging AI, the Company is seeking to streamline drug repurposing, accelerate drug discovery, optimize solid-form identification, and enhance the precision and efficiency of clinical trial monitoring. These advancements are expected to shorten development timelines, reduce costs, and improve the predictability of successful outcomes.

Conduit and Sarborg have completed the initial milestones including the Teach-in Sessions and Proprietary Inputs Validation, tailored to Conduit's portfolio needs. These initial workstreams shape the integration of AI-driven processes to further strengthen Conduit's ability to advance its proprietary assets, including AZD1656, AZD5904, AZD5658, CDT1656, and its AZD1656 cocrystals, with greater efficiency. While Conduit remains focused on delivering impactful therapies to patients through its proposed Phase 2 clinical trials in auto-immune disorders, the Company continually endeavours to remain at the forefront of innovation in pharmaceutical development.